TrialPloS one2024

Cost-effectiveness analysis of Shexiang Baoxin Pill (MUSKARDIA) as the add-on treatment to standard therapy for stable coronary artery disease in China.

Jie Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.